scholarly journals Genetic Aspects of Inflammation and Immune Response in Stroke

2020 ◽  
Vol 21 (19) ◽  
pp. 7409
Author(s):  
Dejan Nikolic ◽  
Milena Jankovic ◽  
Bojana Petrovic ◽  
Ivana Novakovic
Keyword(s):  
Immune Response ◽  
Brain Plasticity ◽  
Treatment Modalities ◽  
Genetic Determinants ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Stroke Treatment ◽  
Complex Processes ◽  
Non Coding Rnas

Genetic determinants play important role in the complex processes of inflammation and immune response in stroke and could be studied in different ways. Inflammation and immunomodulation are associated with repair processes in ischemic stroke, and together with the concept of preconditioning are promising modes of stroke treatment. One of the important aspects to be considered in the recovery of patients after the stroke is a genetic predisposition, which has been studied extensively. Polymorphisms in a number of candidate genes, such as IL-6, BDNF, COX2, CYPC19, and GPIIIa could be associated with stroke outcome and recovery. Recent GWAS studies pointed to the variant in genesPATJ and LOC as new genetic markers of long term outcome. Epigenetic regulation of immune response in stroke is also important, with mechanisms of histone modifications, DNA methylation, and activity of non-coding RNAs. These complex processes are changing from acute phase over the repair to establishing homeostasis or to provoke exaggerated reaction and death. Pharmacogenetics and pharmacogenomics of stroke cures might also be evaluated in the context of immuno-inflammation and brain plasticity. Potential novel genetic treatment modalities are challenged but still in the early phase of the investigation.

The bird dancer and the warrior king: Divergent lived experiences of Tourette syndrome in Bali

2017 ◽  
Vol 54 (4) ◽  
pp. 540-561 ◽  
Author(s):  
Robert Lemelson ◽  
Annie Tucker
Keyword(s):  
Lived Experience ◽  
Tourette Syndrome ◽  
Subjective Experience ◽  
Influential Factors ◽  
Treatment Modalities ◽  
Visual Anthropology ◽  
Subjective Experiences ◽  
Term Outcome ◽  
Long Term Outcome

In the past two decades, ethnographic, epidemiological and interdisciplinary research has robustly established that culture is significant in determining the long-term outcomes of people with neurodevelopmental, neuropsychiatric and mood disorders. Yet these cultural factors are certainly not uniform across discrete individual experiences. Thus, in addition to illustrating meaningful differences for people with neuropsychiatric disorder between different cultures, ethnography should also help detail the variations within a culture. Different subjective experiences or outcomes are not solely due to biographical idiosyncrasies—rather, influential factors arising from the same culture can have different impacts on different people. When taking a holistic and intersectional perspective on lived experience, it is crucial to understand the interaction of these factors for people with neuropsychiatric disorders. This paper teases apart such interactions, utilizing comparative case studies of the disparate subjective experiences and illness trajectories of two Balinese people with Tourette syndrome who exhibit similar symptoms. Based on longitudinal person-centered ethnography integrating clinical, psychological, and visual anthropology, this intersectional approach goes beyond symptom interpretation and treatment modalities to identify gendered embodiment and marital practices as influenced by caste to be significant determinants in subjective experience and long-term outcome.

Long-term outcome after urethral rupture: A comparison of different treatment modalities

2017 ◽  
Vol 16 (3) ◽  
pp. e1190-e1191
Author(s):  
M.A. Furrer ◽  
M. Paerli ◽  
G. Thalmann ◽  
B. Roth
Keyword(s):  
Treatment Modalities ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Urethral Rupture

Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2258-2258
Author(s):  
Hans-Jochem Kolb ◽  
Dagmar Bund ◽  
Helga Schmetzer ◽  
Christoph Schmid ◽  
Raymund Buhmann ◽  
...  
Keyword(s):  
Conflicts Of Interest ◽  
Allogeneic Transplantation ◽  
Myelogenous Leukemia ◽  
Long Term Results ◽  
Treatment Modalities ◽  
Simultaneous Treatment ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Gm Csf

Abstract Abstract 2258 Poster Board II-235 The long-term outcome of donor lymphocyte infusions (DLI) as first line treatment of relapse of chronic myeloid leukemia (CML) after allogeneic stem cell transplantation was studied and compared to other treatment modalities. Forty five patients were treated with DLI and 36 without DLI. Patients given DLI first did not differ significantly from those given other treatments in gender, age, donor, gender and histocompatibility of the donor, source of stem cells (blood vs marrow), depletion of T cells, stage of the disease, time from diagnosis and year at the time of transplant, acute and chronic graft-versus-host disease (GVHD) and remission duration. The survival of the DLI group was 66.4 percent at 10 and 15 years after transplantation, it was 42.2 and 23.8 percent respectively in the non-DLI group (p=0.019, log rank). Excluding patients with early relapse in the first 6 months the survival of the DLI group was 78 percent at 15 and 20 years, 70 and 26 percent respectively of the non-DLI group (p=0.009). Recurrent leukemia was the predominant cause of death in both groups (11 of 14 patients of the DLI-, 21 of 23 patients of the non-DLI group). Three patients in the DLI group died of recurrent infections, bronchiolitis obliterans (BO) and heart failure respectively, and 2 patients of BO in the non-DLI group. The proportion of surviving patients with positive PCR for bcr/abl was not different in both groups (2 of 13 patients of the non-DLI and 7 of 30 patients in the DLI group). The better survival of the DLI group indicates a better control of residual leukemia by a persistent immune effect. The response to DLI was improved by simultaneous treatment with low doses of interferon-a and GM-CSF. The combination of these cytokines without DLI and transplantation remains to be defined in patients that do not tolerate or respond incompletely to Imatinib. The role of immunotherapy for induction and maintenance of remission is well established in transplant patients. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Stroke treatment in Stroke Unit: from scientific evidences to clinical practice

2013 ◽  
pp. 239-243
Author(s):  
Michele Stornello ◽  
Filomena Pietrantonio
Keyword(s):  
Early Stage ◽  
Integrated Approach ◽  
Stroke Care ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Stroke Treatment ◽  
Care Approach ◽  
Long Term Follow Up ◽  
Set Up

Background: In themanagement of stroke disease, evidences fromthe literature demonstrate that the introduction of stroke units, hospital wards with dedicated beds providing intensive care within 48 hours of symptoms’ onset, produced a real improvement in the outcome, reducing in-hospital fatality cases and increasing the proportion of patients independently living in long term follow-up. Discussion: The article focuses on stroke disease-management, suggesting a stroke integrated approach for the admission of patients on dedicated beds, in order to extend the ‘‘stroke care’’ approach outcomes to as many hospitals as possible in Italy. This approach implies the set up of a stroke network for an effective patients’ stratification according to the severity of the illness at debut; the set up of an integrated team of specialists in hospital management of the acute phase (first 48 hours) and a timely rehabilitation treatment. Ultimately the hospital should be organized according to department’s semi-intensive areas in order to assure to the patients, in the early stage of the disease, a timely high intensity care aimed to improve the long term outcome.

scholarly journals Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score

2020 ◽  
Vol 145 (5) ◽  
pp. 1452-1463 ◽  
Author(s):  
Victoria Katharina Tesch ◽  
Hassan Abolhassani ◽  
Bella Shadur ◽  
Joachim Zobel ◽  
Yuliya Mareika ◽  
...  
Keyword(s):  
Immune Deficiency ◽  
Treatment Modalities ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Lrba Deficiency
Sign in / Sign up

Export Citation Format

Share Document